Target Details
| UniProt AC | P23458 |
|---|---|
| Gene Symbol | JAK1 |
| Protein Name | Tyrosine-protein kinase JAK1 |
| Organism | Homo sapiens |
| Entry Name | |
| Organism Category | Human |
| Pfam Domains | PF18379 (FERM_F1) PF18377 (FERM_F2) PF17887 (Jak1_Phl) PF07714 (PK_Tyr_Ser-Thr) PF21990 (SH2_1) |
Summary
- Multi-target molecules 8,920
- Clinical molecules 14
- Avg pChEMBL 8.26
KEGG Pathways (28)
- Coronavirus disease - COVID-19
- EGFR tyrosine kinase inhibitor resistance
- Epstein-Barr virus infection
- Hepatitis B
- Hepatitis C
- Herpes simplex virus 1 infection
- Human T-cell leukemia virus 1 infection
- Human cytomegalovirus infection
- Human papillomavirus infection
- Influenza A
- JAK-STAT signaling pathway
- Kaposi sarcoma-associated herpesvirus infection
- Leishmaniasis
- Measles
- NOD-like receptor signaling pathway
- Necroptosis
- Osteoclast differentiation
- PD-L1 expression and PD-1 checkpoint pathway in cancer
- PI3K-Akt signaling pathway
- Pancreatic cancer
- Pathways in cancer
- Signaling pathways regulating pluripotency of stem cells
- Th1 and Th2 cell differentiation
- Th17 cell differentiation
- Toll-like receptor signaling pathway
- Toxoplasmosis
- Tuberculosis
- Viral carcinogenesis
Associated Diseases (1)
Active Molecules (8,920)
| InChIKey | pChEMBL | Type | Targets | Clinical | |
|---|---|---|---|---|---|
ZCIBTYIZEOBKOI
|
10.5 | IC50 | 4 | — | |
CCMBJIATBMXYFC
|
10.4 | IC50 | 4 | — | |
ZSTUJCOZGCERSU
|
10.4 | IC50 | 4 | — | |
KFFMTKTXYCWBCR
|
10.4 | IC50 | 4 | — | |
GOVBNJVVLBICAP
|
10.4 | IC50 | 4 | — | |
BGLUIKXULQMNGE
|
10.4 | IC50 | 2 | — | |
CQAQZMPRLYALAL
|
10.4 | IC50 | 2 | — | |
GMCWGJVNSYEKAF
|
10.4 | IC50 | 2 | — | |
HCKWPDUQMDFWHY
|
10.4 | IC50 | 2 | — | |
JJNJKRSPRRVHCD
|
10.4 | IC50 | 2 | — | |
JWZIADYHSJEHSW
|
10.4 | IC50 | 2 | — | |
KZDKKBCVTWYPRV
|
10.4 | IC50 | 2 | — | |
LKYNKWVSJBBRNP
|
10.4 | Ki | 4 | — | |
OICGZDBPQBIFLV
|
10.4 | IC50 | 2 | — | |
PDUVQCXXOZUIED
|
10.4 | IC50 | 2 | — | |
QHXCXCRTHJNOIR
|
10.4 | IC50 | 2 | — | |
RINWDSCUVKTALQ
|
10.4 | Ki | 4 | — | |
SSLGYCGYZMIQJD
|
10.4 | IC50 | 2 | — | |
ULCJJWMOPWEMQM
|
10.4 | IC50 | 2 | — | |
ZFRAEDVTZFTQHU
|
10.4 | IC50 | 2 | — | |
XOBYWVCCKFXUKO
|
10.4 | IC50 | 4 | — | |
VMLVHRAAZGJBIV
|
10.4 | IC50 | 4 | — | |
LLXUFTFQOVBHRV
|
10.4 | IC50 | 4 | — | |
BRIUDIRHWGESSC
|
10.3 | IC50 | 4 | — | |
AXLSAJBAFIAJCA
|
10.3 | IC50 | 2 | — | |
CVHSFUPKHBNGLI
|
10.3 | Ki | 2 | — | |
CVHSFUPKHBNGLI
|
10.3 | Ki | 2 | — | |
DFAZSOUFLNOONE
|
10.3 | Ki | 4 | — | |
DFAZSOUFLNOONE
|
10.3 | Ki | 4 | — | |
GPOGKSDOWYRIMA
|
10.3 | Ki | 2 | — | |
GPOGKSDOWYRIMA
|
10.3 | Ki | 4 | — | |
HDTXWUHMYZRQFF
|
10.3 | IC50 | 3 | — | |
IMMLXIZVTUKHEQ
|
10.3 | Ki | 4 | — | |
LBBZLXMPUULIGG
|
10.3 | IC50 | 2 | — | |
LKYNKWVSJBBRNP
|
10.3 | Ki | 2 | — | |
LXCJYFUAMDZSGA
|
10.3 | Ki | 4 | — | |
MDGKQKHJTRCFKH
|
10.3 | IC50 | 2 | — | |
MDGKQKHJTRCFKH
|
10.3 | IC50 | 2 | — | |
PJTVQALTARBQFE
|
10.3 | Ki | 2 | — | |
PLOAUINIELSVFC
|
10.3 | Ki | 4 | — | |
QHHRTNNXPWXSMX
|
10.3 | Ki | 4 | — | |
TWGKDJAUEJWZFH
|
10.3 | IC50 | 2 | — | |
UNKLRGOHFNDILM
|
10.3 | Ki | 2 | — | |
VOEVWNYDAOBKRA
|
10.3 | IC50 | 2 | — | |
VVUPFHUSDJLFEM
|
10.3 | Ki | 4 | — | |
WISDJQVWPWYDHB
|
10.3 | IC50 | 2 | — | |
YAHQISLGSOFLRU
|
10.3 | Ki | 4 | — | |
YCMGUXRIFKZINL
|
10.3 | IC50 | 2 | — | |
ZMFNZTSECWNPOO
|
10.3 | IC50 | 2 | — | |
OZDFKECLFIDGPK
|
10.3 | IC50 | 4 | — |